Autolus Therapeutics plc (NASDAQ:AUTL) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 35.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,220,226 shares of the company's stock after purchasing an additional 6,330,392 shares during the period. Wellington Management Group LLP owned approximately 9.10% of Autolus Therapeutics worth $87,919,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in AUTL. ProShare Advisors LLC purchased a new stake in Autolus Therapeutics in the second quarter valued at about $43,000. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the 3rd quarter valued at approximately $51,000. Daiwa Securities Group Inc. boosted its stake in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC acquired a new stake in Autolus Therapeutics in the 3rd quarter worth approximately $91,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock worth $139,000 after purchasing an additional 14,959 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Analyst Ratings Changes

AUTL has been the subject of several research reports. Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price objective for the company in a research note on Friday, November 15th. The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Stock Performance

NASDAQ AUTL traded up $0.03 on Wednesday, reaching $2.90. 1,563,960 shares of the company's stock traded hands, compared to its average volume of 1,467,714. Autolus Therapeutics plc has a fifty-two week low of $2.69 and a fifty-two week high of $7.45. The firm has a market cap of $771.66 million, a price-to-earnings ratio of -2.37 and a beta of 1.99. The stock has a 50 day moving average price of $3.65 and a 200-day moving average price of $3.87.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter last year, the business earned ($0.26) earnings per share. As a group, equities research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.